Market research
2GT.F Applied Genetic Technologies Corporation
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 24M
- P/E ratio
- Not available
- Analyst target
- 15.67
- Dividend yield
- 0.0%
- Beta
- 1.55
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 24M
- P/E ratio
- Not available
- Analyst target
- 15.67
- Dividend yield
- 0.0%
- Beta
- 1.55
About
About Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in phase 1/2 clinical trials; and achromatopsia that is in phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. Applied Genetic Technologies Corporation was incorporated in 1999 and is based in Alachua, Florida with an additional location in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 2GT.F discussion.
5 years, 5 months ago
Applied Genetic Technologies Corporation is currently in a long term downtrend where the price is trading 19.3% below its 200 day moving average.
From a valuation standpoint, the stock is 95.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 58.6.
Applied Genetic Technologies Corporation's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 79.3% to $-15M since the same quarter in the previous year.
Finally, its free cash flow fell by 56.1% to $-14M since the same quarter in the previous year.
Based on the above factors, Applied Genetic Technologies Corporation gets an overall score of 1/5.